⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
EXEL News
Exelixis Inc
$1.59 Billion PD-1 Resistant Head and Neck Cancer Market Analysis Report 2026: Size, Growth, and Segmentation Insights to 2030
globenewswire.com
CVM
EXEL
MRK
PFE
AZN
RPRX
Colorectal Cancer Advocates Urge Congress to Fund New Research
globenewswire.com
EXAS
EXEL
GSK
GH
ISRG
MRK
NTRA
PFE
Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer
globenewswire.com
RXRX
EXEL
MRK
BMY
GSK
Checkpoint Inhibitor Refractory Cancer Drugs Market to Reach USD 95,548.35 Million by 2032 Amid Rising Post-Checkpoint Inhibitor Sequencing Demand and Combination Treatment Adoption - Credence Research
prnewswire.com
BMY
MRK
REGN
EXEL
AZN
GSK
A Symbol of Crisis: As Colorectal Cancer Deaths Rise, Fight CRC Installs United in Blue on the National Mall
globenewswire.com
AMGN
BMY
EXEL
EXAS
GENK
GSK
JNJ
MRK
NTRA
PFE
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March
businesswire.com
EXEL
Oncology Market Set to Nearly Triple: Here Are Five Companies Leading the Charge
prnewswire.com
MRK
EXEL
LLY
ONCY
GILD
Biogen Announces Board Chair Transition
globenewswire.com
BIIB
ARE
EXEL
Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update
businesswire.com
EXEL
Primmune Therapeutics Appoints Chief Medical Officer and Executive Board Chair; Establishes Melanoma Clinical Study Advisory Board
globenewswire.com
ALGN
AZN
EXEL
VRTX
XNCR